BD and ten23 health® partner to advance efficiency and quality in aseptic manufacturing with RFID-enabled prefillable syringes

Franklin Lakes, N.J. and Basel, Switzerland - Oct 08, 2024: BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and ten23 health, the human-centric and sustainable strategic CDMO partner of choice for the pharmaceutical industry and biotech start-ups, today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

The collaboration aims to pilot an RFID-based solution created by BD to improve manufacturing process efficiency, and provide traceability of individual units. This solution will benefit ten23 health and its customers by ensuring a higher traceability throughout both the manufacturing process and the supply chain. The new traceability solution, branded BD iDFill™ Individual Prefillable Syringe Identification*, involves equipping each PFS with an RFID tag encoded with a unique serial number called the Container Unique Identifier (CUID). This CUID can be scanned at various stages of the manufacturing process, from filling to secondary packaging or any further assembly. By linking the drug code, filling batch, timestamps, and other relevant data with the CUID, the solution provides full container traceability and enables multiple applications, including automated reconciliation, mix-up prevention, and investigation management. This system also helps to quickly identify and trace individual units during production and beyond.

By focusing on individual units instead of batches, BD iDFill™ offers greater process visibility and efficiency. Furthermore, positioning the primary container as a bridge between separate process unit operations - such as filling and inspection - enables ten23 health to leverage the significant potential of existing process data and opens up new possibilities for advanced manufacturing applications both on-site and beyond. For more information, visit BD iDFill.

"BD iDFill™ aims to transform the way we approach quality and efficiency in the fill & finish process by extending the role of the PFS from a drug container to a digital enabler," said Patrick Jeukenne, president of BD Medical - Pharmaceutical Systems. "We expect this innovation will harness the vast potential of data in manufacturing and bring a new level of transparency to the pharmaceutical fill & finish process."

"We are excited about this collaboration with BD, as it aligns perfectly with our commitment to innovation and quality," said Hanns-Christian Mahler, CEO of ten23 health.

"This new RFID-based traceability solution has the potential to further enhance our manufacturing processes and also provides significant benefits to our pharmaceutical customers by ensuring greater transparency and reducing risks," added Andrea Allmendinger, CSO of ten23 health.

*BD iDFill™ Individual Prefillable Syringe Identification is a product in development; some statements are forward-looking and are subject to a variety of risks and uncertainties.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.

About ten23 health
ten23 health^®, located in Basel and Visp, Switzerland, is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: we develop, manufacture, and test modern medicines. We support our clients in developing differentiated, stable, usable, and safe injectable treatment options for patients.
ten23 health^® combines the latest scientific findings with proven and tested world-class industry and regulatory expertise to forge new paths for supporting clients. We provide our innovative services in a fair and sustainable manner, respecting people's health and the future of our planet. ten23 health^® is a B-Corp member and solidly financed through the long-term commitment of 3i Group, an internationally reputable equity partner.

About the company's name
The numeric value for the number of molecules in a sample of one mol is called Avogadro constant and equals 6.022 * 10 23. Gram quantities of material contain the incredible number of 10 23 atoms, which was an important discovery to understand the composition of matter: The world is built from small units, and not a homogeneous mass.

About 3i Group
3i is an investment company with two complementary businesses, Private Equity and Infrastructure, and invests in mid-market companies headquartered in Europe and North America. 3i's Private Equity team provides investment solutions for growing companies, backing entrepreneurs and management teams of companies with an EV typically between €100m - €500m. 3i backs international growth plans, providing access to its network and expertise to accelerate the growth of companies across the consumer, healthcare, industrial and private label, and services and software industries.

Contacts:

BD:
Troy Kirkpatrick, VP, Public Relations; [email protected]; +1 858 617 2361
Adam Reiffe, Sr. Director, Investor Relations; [email protected]; +1 201 847 6927

ten23 health:
Marija Petrovic, [email protected]; +41 78 694 87 33

3i Group:
Kathryn van der Kroft, [email protected]; +44 20 7975 3021

Public link

Please use the above public link if you want to share this noodl on another website.